

Workshop on Paediatric Investigation Plans in Type 2 Diabetes Mellitus

Conclusions

Paolo Tomasi MD PhD

Head of Paediatric Medicines, EMA












NIHR Medicines for Children Research Network (MCRN)



Clinical Research Network

Percentage of Adopted Industry Studies with Associated PIPs




industry@mcrn.org.uk - www.mcrn.org.uk



Will all Paediatric Investigation Plans be completed?

Completion of studies under BPCA written request (optional, but 80% suggested by applicant)



Source: IOM report on "Safe and Effective Medicines for Children: Pediatric Studies Conducted Under BPCA and PREA"

Main concerns for pharma companies (feasibility):

- Few available patients in total for all the studies.
- Widespread insulin (and metformin) use needs to be addressed – weaning not always feasible.
- 30% patients to be recruited in EU-like countries: difficult to achieve due to rarity in EU
- Many patients do not meet HbA1c inclusion
 criteria



Potential solutions

- Broadened role for extrapolation (for efficacy) / sample size reduction
 - ✓ Use of Bayesian methods with adult priors
 - ✓ Acceptance of lower significance levels (p=0.07, p=0.10)
 - ✓ Safety study only (pre or post authorization in children?)
- Studies in related diseases (prediabetes? T1DM?)
- Staggered development of products (in same class) / deferrals
- Broadened inclusion criteria:
 - ✓ For insulin treatment
 - ✓ For age (up to 22? 25?)
 - ✓ For HbA1c range
 - ✓ For geographical origin (non-EU)
 - ✓ What else?
- **Multi-company study** (paediatric incentive and obligations are irrespective of outcome of studies)
- Single company with multiple agents
- Simplification of PK studies (peak and trough levels, dried blood spots)

Conclusions

- Number of patients required is high (and it's a minimum number).
- A change in paradigm for diabetes PIPs seems necessary, to maximize feasibility and obtain significant data.
- Staggered development, followed potentially by greater extrapolation and/or reduced requirements could be a solution.
- Several of the proposed solutions may be applicable in practice.
- SAWP/CHMP needs to be included in the equation; Extrapolation working group will act as the glue (chairs of SAWP and CHMP are members).
- Companies may re-consider their options (multi-company studies, modification of previously agreed PIPs...)